2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM: Abstract Number: 2738

The Effect of Pregnancy on Disease Activity Outcomes in Psoriatic Arthritis Patients

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

9:00AM-11:00AM: Abstract Number: 2920

The Effect of Rituximab on B Cells in Skin and Peripheral Blood in Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster III

9:00AM-11:00AM: Abstract Number: 2593

The Effect of Tofacitinib on Bone Mineral Density in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2315

The Effectiveness of Social Media in Recruiting for Rare Rheumatic Diseases

Muscle Biology, Myositis and Myopathies - Poster II: Clinical

9:00AM-11:00AM: Abstract Number: 2609

The Effectiveness of Zoster Vaccine in RA Patients Subsequently Treated up to 19 Months with Tofacitinib

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2590

The Efficacy of Additional Immunoadsorption on the Modulation of Disease Activity in Patients with Severe Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2183

The Electronic Osteoarthritis Knee and Hip Quality of Life (OAKHQOL) Questionnaire: A Useful and Valid Alternative to Measure Health-Related Quality of Life in Knee Osteoarthritis

Epidemiology and Public Health - Poster III

9:00AM-11:00AM: Abstract Number: 2213

The Four Stages of Fibromyalgia: Potential for More Precise Treatment Approaches

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes - Poster II: Clinical Focus

9:00AM-11:00AM: Abstract Number: 2193

The Frequency of and Patient Characteristics Associated with Fear of Movement in Adults with Symptomatic Knee Osteoarthritis

Epidemiology and Public Health - ARHP Poster

9:00AM-11:00AM: Abstract Number: 2592

The Impact of Biologic Therapy Introduction on Hip and Knee Replacement Among Rheumatoid Arthritis Patients: An Interrupted Time Series Analysis Using the Clinical Practice Research Datalink

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2346

The Improving Motivation for Physical Activity in Arthritis Clinical Trial for Adults with Knee Osteoarthritis and Rheumatoid Arthritis

Osteoarthritis – Clinical Aspects - Poster II

9:00AM-11:00AM: Abstract Number: 2900

The Incidence and Prevalence of Systemic Sclerosis in Northwestern Part of Turkey

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster III

9:00AM-11:00AM: Abstract Number: 2296

The Influence of Androgen Deprivation Therapy on Serum Uric Acid Level

Metabolic and Crystal Arthropathies - Poster II: Epidemiology and Mechanisms of Disease

9:00AM-11:00AM: Abstract Number: 2272

The Influence of Genetic Variants on Renal Uric Acid Excretion in Response to Frusemide

Metabolic and Crystal Arthropathies - Poster II: Epidemiology and Mechanisms of Disease

9:00AM-11:00AM: Abstract Number: 2616

The JAK1-Selective Inhibitor Filgotinib Displays an Anti-Inflammatory Biomarker Signature in Rheumatoid Arthritis Patients

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].